Ovid Therapeutics Inc.
OVID
$1.22
$0.087.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,070.95% | 15.61% | 44.39% | 113.30% | 186.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,070.95% | 15.61% | 44.39% | 113.30% | 186.29% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,070.95% | 15.61% | 44.39% | 113.30% | 186.29% |
| SG&A Expenses | -17.85% | -3.52% | -3.48% | -9.26% | -7.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.75% | -3.05% | 9.96% | 28.19% | 24.25% |
| Operating Income | 37.14% | 3.20% | -9.72% | -27.72% | -23.65% |
| Income Before Tax | -28.34% | 50.72% | 49.50% | 33.02% | 39.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.34% | 50.72% | 49.50% | 33.02% | 39.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.34% | 50.72% | 49.50% | 33.02% | 39.58% |
| EBIT | 37.14% | 3.20% | -9.72% | -27.72% | -23.65% |
| EBITDA | 37.46% | 3.33% | -9.74% | -28.08% | -24.02% |
| EPS Basic | -28.50% | 51.07% | 49.42% | 34.81% | 41.24% |
| Normalized Basic EPS | -14.64% | 48.49% | 38.77% | 22.59% | 29.23% |
| EPS Diluted | -28.06% | 51.01% | 49.42% | 34.24% | 40.86% |
| Normalized Diluted EPS | -14.57% | 48.45% | 38.73% | 22.54% | 29.18% |
| Average Basic Shares Outstanding | 0.42% | 0.49% | 0.46% | 0.42% | 0.36% |
| Average Diluted Shares Outstanding | 0.32% | 0.59% | 0.56% | 0.52% | 0.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |